The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment.
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
The CRO is working with PWNHealth and Fulgent Genetics to enhance its monitoring program, including the addition of at-home COVID-19 testing capabilities.
The two organizations will collaborate on development of synthetic arms for clinical studies, drawing from millions of patient records and trial subject.
Conducted via a partnership between Parexel and CISCRP, the study reveals insights about the needs and concerns of pediatric patients and their families.
The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.
A leader from the IQVIA company explains how the boom in the volume and quality of data, and advanced analysis, can speed and streamline drug development.
The Medical Data Platform, an RPM solution from VivaLNK, handles clinical trials, cardiac monitoring, remote and in-patient monitoring and other tasks.
A leader from the clinical trial solutions firm talks about the drive toward conducting trials without sites, and why that idea might lead to problems.
The head of the CRO’s Global Center of Excellence for Decentralized Clinical Trial Strategy outlines key developments in 2020, and keys to success in 2021.
